Literature DB >> 1722936

Bovine herpesvirus-1 (infectious bovine rhinotracheitis virus)-based viral vector which expresses foot-and-mouth disease epitopes.

M Kit1, S Kit, S P Little, R D Di Marchi, C Gale.   

Abstract

A recombinant infectious bovine rhinotracheitis virus (IBRV) vector has been constructed to express bovine growth hormone signal sequence plus a foot-and-mouth disease virus [FMDV (O1K)] capsid protein (VP1) epitope as the N-terminal sequence of an IBRV glycoprotein gIII fusion protein on the surface of virus infected cells and on the surface of virus particles. Sequences encoding the first 38 amino acids of IBRV gIII were deleted from the recombinant to avoid redundant glycoprotein signal sequences, but IBRV gIII epitopes detected by anti-gIII monoclonal antibodies were retained. Phenotypes were confirmed by in situ immunostaining of virus plaques with anti-FMDV peptide sera, by immunogold staining of permeabilized- and non-permeabilized infected cells, and by virus neutralization experiments with anti-FMDV peptide sera. Vaccination with the IBRV-FMDV recombinant induced protective levels of anti-FMDV antibodies in calves and protected them from challenge with virulent IBRV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722936     DOI: 10.1016/0264-410x(91)90243-y

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  The class II membrane glycoprotein G of bovine respiratory syncytial virus, expressed from a synthetic open reading frame, is incorporated into virions of recombinant bovine herpesvirus 1.

Authors:  G Kühnle; A Heinze; J Schmitt; K Giesow; G Taylor; I Morrison; F A Rijsewijk; J T van Oirschot; G M Keil
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 3.  BHV-1: new molecular approaches to control a common and widespread infection.

Authors:  L Turin; S Russo; G Poli
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

4.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

Authors:  J P Langeveld; J I Casal; A D Osterhaus; E Cortés; R de Swart; C Vela; K Dalsgaard; W C Puijk; W M Schaaper; R H Meloen
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Construction of bovine herpesvirus-1 (BHV-1) recombinants which express pseudorabies virus (PRV) glycoproteins gB, gC, gD, and gE.

Authors:  H Otsuka; X Xuan
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Expression of porcine pseudorabies virus genes by a bovine herpesvirus-1 (infectious bovine rhinotracheitis virus) vector.

Authors:  S Kit; H Otsuka; M Kit
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  Genetic recombination of pseudorabies virus: evidence that homologous recombination between insert sequences is less frequent than between autologous sequences.

Authors:  K L Glazenburg; R J Moormann; T G Kimman; A L Gielkens; B P Peeters
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 8.  Viral vectors for veterinary vaccines.

Authors:  M Sheppard
Journal:  Adv Vet Med       Date:  1999

Review 9.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

10.  Blocking ELISA for distinguishing infectious bovine rhinotracheitis virus (IBRV)-infected animals from those vaccinated with a gene-deleted marker vaccine.

Authors:  S Kit; H Otsuka; M Kit
Journal:  J Virol Methods       Date:  1992-10       Impact factor: 2.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.